Nanofiber-based delivery of therapeutic peptides to the brain

Chemistry

Text available via DOI:

https://doi.org/10.1021/nn305193d
Final published version

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Nanofiber-based delivery of therapeutic peptides to the brain. / Mazza, Mariarosa; Notman, Rebecca; Anwar, Jamshed et al.
In: ACS Nano, Vol. 7, No. 2, 26.02.2013, p. 1016-26.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Mazza, M, Notman, R, Anwar, J, Rodger, A, Hicks, M, Parkinson, G, McCarthy, D, Daviter, T, Moger, J, Garrett, N, Mead, T, Briggs, M, Schätzlein, AG & Uchegbu, IF 2013, 'Nanofiber-based delivery of therapeutic peptides to the brain', ACS Nano, vol. 7, no. 2, pp. 1016-26. https://doi.org/10.1021/nn305193d

APA

Mazza, M., Notman, R., Anwar, J., Rodger, A., Hicks, M., Parkinson, G., McCarthy, D., Daviter, T., Moger, J., Garrett, N., Mead, T., Briggs, M., Schätzlein, A. G., & Uchegbu, I. F. (2013). Nanofiber-based delivery of therapeutic peptides to the brain. ACS Nano, 7(2), 1016-26. https://doi.org/10.1021/nn305193d

Vancouver

Mazza M, Notman R, Anwar J, Rodger A, Hicks M, Parkinson G et al. Nanofiber-based delivery of therapeutic peptides to the brain. ACS Nano. 2013 Feb 26;7(2):1016-26. doi: 10.1021/nn305193d

Author

Mazza, Mariarosa ; Notman, Rebecca ; Anwar, Jamshed et al. / Nanofiber-based delivery of therapeutic peptides to the brain. In: ACS Nano. 2013 ; Vol. 7, No. 2. pp. 1016-26.

Bibtex

@article{0df3ebe6db65423497e306a63dab1377,

title = "Nanofiber-based delivery of therapeutic peptides to the brain",

abstract = "The delivery of therapeutic peptides and proteins to the central nervous system is the biggest challenge when developing effective neuropharmaceuticals. The central issue is that the blood-brain barrier is impermeable to most molecules. Here we demonstrate the concept of employing an amphiphilic derivative of a peptide to deliver the peptide into the brain. The key to success is that the amphiphilic peptide should by design self-assemble into nanofibers wherein the active peptide epitope is tightly wrapped around the nanofiber core. The nanofiber form appears to protect the amphiphilic peptide from degradation while in the plasma, and the amphiphilic nature of the peptide promotes its transport across the blood-brain barrier. Therapeutic brain levels of the amphiphilic peptide are achieved with this strategy, compared with the absence of detectable peptide in the brain and the consequent lack of a therapeutic response when the underivatized peptide is administered.",

author = "Mariarosa Mazza and Rebecca Notman and Jamshed Anwar and Alison Rodger and Matthew Hicks and Gary Parkinson and Dave McCarthy and Tina Daviter and Julian Moger and Natalie Garrett and Tania Mead and Michael Briggs and Sch{\"a}tzlein, {Andreas G.} and Uchegbu, {Ijeoma F.}",

year = "2013",

month = feb,

day = "26",

doi = "10.1021/nn305193d",

language = "English",

volume = "7",

pages = "1016--26",

journal = "ACS Nano",

publisher = "American Chemical Society",

number = "2",

}

RIS

TY - JOUR

T1 - Nanofiber-based delivery of therapeutic peptides to the brain

AU - Mazza, Mariarosa

AU - Notman, Rebecca

AU - Anwar, Jamshed

AU - Rodger, Alison

AU - Hicks, Matthew

AU - Parkinson, Gary

AU - McCarthy, Dave

AU - Daviter, Tina

AU - Moger, Julian

AU - Garrett, Natalie

AU - Mead, Tania

AU - Briggs, Michael

AU - Schätzlein, Andreas G.

AU - Uchegbu, Ijeoma F.

PY - 2013/2/26

Y1 - 2013/2/26

N2 - The delivery of therapeutic peptides and proteins to the central nervous system is the biggest challenge when developing effective neuropharmaceuticals. The central issue is that the blood-brain barrier is impermeable to most molecules. Here we demonstrate the concept of employing an amphiphilic derivative of a peptide to deliver the peptide into the brain. The key to success is that the amphiphilic peptide should by design self-assemble into nanofibers wherein the active peptide epitope is tightly wrapped around the nanofiber core. The nanofiber form appears to protect the amphiphilic peptide from degradation while in the plasma, and the amphiphilic nature of the peptide promotes its transport across the blood-brain barrier. Therapeutic brain levels of the amphiphilic peptide are achieved with this strategy, compared with the absence of detectable peptide in the brain and the consequent lack of a therapeutic response when the underivatized peptide is administered.

AB - The delivery of therapeutic peptides and proteins to the central nervous system is the biggest challenge when developing effective neuropharmaceuticals. The central issue is that the blood-brain barrier is impermeable to most molecules. Here we demonstrate the concept of employing an amphiphilic derivative of a peptide to deliver the peptide into the brain. The key to success is that the amphiphilic peptide should by design self-assemble into nanofibers wherein the active peptide epitope is tightly wrapped around the nanofiber core. The nanofiber form appears to protect the amphiphilic peptide from degradation while in the plasma, and the amphiphilic nature of the peptide promotes its transport across the blood-brain barrier. Therapeutic brain levels of the amphiphilic peptide are achieved with this strategy, compared with the absence of detectable peptide in the brain and the consequent lack of a therapeutic response when the underivatized peptide is administered.

UR - http://www.scopus.com/inward/record.url?scp=84874406744&partnerID=8YFLogxK

U2 - 10.1021/nn305193d

DO - 10.1021/nn305193d

M3 - Journal article

C2 - 23289352

VL - 7

SP - 1016

EP - 1026

JO - ACS Nano

JF - ACS Nano

IS - 2

ER -

Research

Links

Text available via DOI: